# Novo-Nordisk A/S (NVO) stock analysis and sentiment

Canonical page: https://synoptiv.com/stock/NVO
Methodology: https://synoptiv.com/methodology
Author: Synoptiv Research Engine

Last analyzed: Aug 23, 2026

Novo-Nordisk A/S (NVO) last closed at $46.74, around the middle of its 52-week range of $35.12–$64.16. Composite market sentiment across 1 analysis is neutral (+7 on a −100 to +100 scale), as of Aug 23, 2026.

## What the data says

Novo Nordisk closed at $46.74, sitting in the lower half of a 52-week range that runs from $35.12 to $64.16. That band is wide — the high is roughly 83% above the low — and the current price sits about 33% below the high while holding well above the trough, so the past year has involved a substantial repricing rather than a narrow, range-bound drift.

At a $207 billion market capitalization, the stock trades at about 11.4 times trailing earnings and 13.6 times forward estimates, meaning the market is paying less for the next twelve months of expected profit than for the last twelve — a pattern consistent with earnings expectations easing rather than expanding. Those multiples sit against a business that remains highly profitable, with a 35.3% profit margin, though revenue growth of 2.1% is modest by comparison. The price-to-book ratio of 6.67 shows the market still values the company at a substantial premium to its accounting equity, and a beta of 0.35 indicates the shares have moved considerably less than the broader market. The dividend yield stands at 3.84%.

The recent news flow is dominated less by Novo Nordisk itself than by the competitive field around it. Most headlines concern rivals in obesity and weight-loss treatment: Eli Lilly's European approval for a weight-loss pill and the timing of its next FDA filing, Pfizer's berobenatide positioned against Wegovy and Zepbound, and coverage of Viking Therapeutics. Two items are company-specific — a Dutch court injunction Novo Nordisk won against an unapproved compounded semaglutide nasal spray, and a routine disclosure of share trading by board members and executives. The overall tilt is toward sector-level competitive developments, with several stories explicitly framing Novo Nordisk's performance in comparison to Eli Lilly's.

## About Novo-Nordisk A/S

Novo Nordisk A/S is a Danish pharmaceutical company that researches, develops, manufactures, and distributes medicines, with a long-standing focus on diabetes care. Founded in 1923 and headquartered in Bagsværd, Denmark, it reports through two business segments: Obesity and Diabetes Care, and Rare Disease. The first covers treatments for diabetes and obesity along with cardiovascular and other emerging therapy areas; the second addresses rare blood and endocrine disorders and hormone replacement therapy.

Alongside its injectable and oral therapies, the company supplies delivery and support products, including connected insulin pens such as NovoPen 6 and NovoPen Echo Plus, growth hormone pens and injection needles, and the Dose Check application for insulin dose guidance. Its products are sold across Europe, North America, Latin America, Japan, Korea, Greater China, Southeast Asia, Oceania, the Middle East, and Africa.

## Company profile

- Symbol: NVO
- Exchange: NYSE
- Security type: Stock
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Composite sentiment: neutral (7 on a -100 to +100 scale)

## Key statistics

| Metric | Value |
| --- | ---: |
| Market capitalization | $206.69B |
| Enterprise value | $302.11B |
| Trailing P/E | 11.4 |
| Forward P/E | 13.59 |
| Price to book | 6.67 |
| Price to sales | 0.63 |
| Dividend yield | 3.84% |
| Beta | 0.35 |
| Net margin | 35.35% |
| Revenue growth | 2.10% |
| Earnings growth | -20.60% |
| 52-week high | $64.16 |
| 52-week low | $35.12 |
| Average volume | 12.4M |

## Related stocks

- NOVO B.CO
- ALK B.CO
- HLUN A.CO
- PEG.CO
- STENO.CO

## Recent news

- [Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can](https://www.fool.com/investing/2026/08/23/eli-lilly-and-novo-nordisk-cant-treat-this-form-of/) — Aug 23, 2026
- [Prediction: Eli Lilly Could Be One of the Biggest Winners of the Next Decade. Here’s Why.](https://247wallst.com/investing/2026/08/23/prediction-eli-lilly-could-be-one-of-the-biggest-winners-of-the-next-decade-heres-why/) — Aug 23, 2026
- [2 Biotech Stocks Shaping Up for Major Breakouts](https://www.marketbeat.com/articles/2-biotech-stocks-shaping-up-for-major-breakouts/?utm_source=yahoofinance&utm_medium=yahoofinance) — Aug 22, 2026
- [Eli Lilly: Shaking Off Competition From The Dethroned Novo Nordisk](https://seekingalpha.com/article/4939364-eli-lilly-shaking-off-competition-from-dethroned-novo-nordisk) — Aug 22, 2026
- [SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing](https://stocktwits.com/news-articles/markets/equity/srrk-stock-gains-after-company-drops-troubled-novo-nordisk-owned-plant-from-fda-filing/cZY97AgRJVf) — Aug 21, 2026
- [Novo Nordisk: The Pill That Could Close The Gap With Lilly](https://seekingalpha.com/article/4939253-novo-nordisk-the-pill-that-could-close-the-gap-with-lilly) — Aug 21, 2026
- [10 Health Care Stocks Whale Activity In Today’s Session](https://www.benzinga.com/markets/options/26/08/61363397/10-health-care-stocks-whale-activity-today-s-session) — Aug 21, 2026
- [Scholar Rock Removes Catalent Indiana From Apitegromab BLA as Fill-Finish Facility](https://finance.yahoo.com/healthcare/articles/scholar-rock-removes-catalent-indiana-133515854.html) — Aug 21, 2026
- [Eli Lilly Is In A Race with Novo Nordisk But Its Stock Is The Clear Winner](https://www.investors.com/stock-lists/sector-leaders/zepbound-eli-lilly-stock-lly-mounjaro-foundayo/?src=A00220&yptr=yahoo) — Aug 21, 2026
- [Hims & Hers Health (HIMS) & Novo Nordisk A/S (NVO): Two Weight-Loss Pill Players Just Got Punished for Growing Fast](https://finance.yahoo.com/healthcare/articles/hims-hers-health-hims-novo-015614960.html) — Aug 21, 2026

## Frequently asked questions

### What is the current market sentiment for NVO?

As of Aug 23, 2026, Novo-Nordisk A/S (NVO) carries neutral (+7 on a −100 to +100 scale) composite sentiment. The score fuses recent news tone, analyst recommendations, technical posture, insider and congressional activity, and market attention into a single figure. The full breakdown of each component is in the report.

### How has NVO stock been performing?

Novo-Nordisk A/S last closed at $46.74, around the middle of its 52-week range of $35.12–$64.16.

### What is NVO's market cap and valuation?

Novo-Nordisk A/S has a market capitalization of about $206.69B, a trailing P/E of 11.4, a dividend yield of 3.84%.

### What sector is NVO in, and who are its competitors?

Novo-Nordisk A/S operates in the Healthcare sector, specifically Drug Manufacturers - General. Comparable companies include NOVO B.CO, ALK B.CO, HLUN A.CO, PEG.CO, STENO.CO.

### Where can I find a full analysis of NVO?

The full NVO report covers the bull and bear cases, technical signals with entry, stop and target levels, complete financial statements, earnings history, insider and congressional trades, and the conditions that would invalidate the thesis. It requires a free account.

## Important information

This page is generated from public market and company information. Data can be delayed, incomplete, or wrong. It is research and analysis, not financial advice.

- [Methodology](https://synoptiv.com/methodology)
- [Disclosures](https://synoptiv.com/disclosures)
- [Full report](https://synoptiv.com/stock/NVO/v/1) (account and access required)